Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
2241-2260 of 3,900 trials

Metastatic Colorectal Cancer: Telisotuzumab Adizutecan Study

We are investigating a new treatment combination for people with metastatic colorectal cancer to see if it works better and is safer than current standard treatments.

Metastatic Colorectal Cancer≤3 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Ovarian Cancer: Continued Treatment with Olaparib

We are providing ongoing treatment with Olaparib for patients who have benefited from it in a previous study. This trial focuses on monitoring safety while allowing continued access to the medication.

Ovarian CancerBreast CancerProstate Cancer>2 yearsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Sage-319: Safety Study in Healthy Adults

We are testing a new medication called Sage-319 to see how safe it is and how the body handles it. This study helps us understand its effects and potential use in future treatments.

GABAergic Signaling DisordersSafety phase (I)Psychiatry

ENPP1 Deficiency: INZ-701 Study

We are investigating whether the drug INZ-701 can help infants with ENPP1 deficiency by improving survival and preventing heart and respiratory problems. The study aims to see if it can also support physical growth and reduce artery issues.

Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 Deficiency1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyPediatrics

Crohn’s Disease: AZD7798 PET Study

We are examining how different doses of the drug AZD7798 are taken up in the body of patients with Crohn’s disease. This study aims to provide insights into the drug's effects on this condition.

Crohn's Disease1-2 yearsSafety phase (I)Gastroenterology

Non-Small Cell Lung Cancer: Acasunlimab and Pembrolizumab Study

We are evaluating a new combination treatment for patients with advanced non-small cell lung cancer who have already received other therapies. The goal is to see if this combination works better than the standard treatment, docetaxel.

Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Advanced Gastric Cancer: New Drug Combinations

We are studying whether a new combination of trifluridine/tipiracil and oxaliplatin, with or without nivolumab, is more effective than standard treatment for patients with advanced gastric or esophageal cancer. The goal is to improve survival and quality of life for those with HER2 negative cancer.

HER2 Negative Gastric CancerEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesGastroenterologyOncology

Prednisone for Idiosyncratic Hepatotoxicity

We are studying whether prednisone can help reduce liver damage in patients with idiosyncratic hepatotoxicity. The trial will also assess its safety and impact on quality of life compared to a placebo.

Liver Toxicity>2 yearsEfficacy phase (II)6-10 visitsInvestigational MedicinesHepatologyInternal Medicine

Advanced Solid Tumors: OATD-02 Treatment

We are evaluating the safety and potential effectiveness of OATD-02 in patients with advanced or metastatic solid tumors who have completed an earlier study. This research aims to understand how well this treatment works in this specific group.

Advanced Solid Tumors>2 yearsSafety phase (I)Post-Trial Drug AccessOncology

Cancer Treatment: Enhancing Radionuclide Therapy with PARP Inhibitors

We are exploring whether adding PARP inhibitors can improve outcomes for patients receiving Peptide Receptor Radionuclide Therapy for cancer. This study aims to see if the combination leads to better treatment results.

Gastroenteropancreatic Neuroendocrine Tumors>2 yearsSafety phase (I)Internal MedicineOncology

Targeted Therapies for Moderate to Severe Crohn’s Disease

We are studying new targeted treatments for adults with moderate to severe Crohn’s disease. The goal is to evaluate their safety and effectiveness in managing this condition.

Crohn's Disease3-6 monthsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Ulcerative Colitis: RO7790121 Treatment Study

We are studying a new treatment for people with moderately to severely active ulcerative colitis to see if it can help induce remission. The trial will also assess its safety and impact on symptoms and quality of life.

Ulcerative ColitisConfirmation phase (III)Post-Trial Drug AccessCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Juvenile Idiopathic Arthritis: MOVE-JIA Trial

We are comparing two treatment withdrawal strategies for children and adolescents with Juvenile Idiopathic Arthritis in remission. The goal is to see which method better prevents disease flares compared to ongoing stable treatment.

Juvenile Idiopathic Arthritis>2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesInternal MedicineRheumatology

Major Depression: Samyr® Tablet Study

We are investigating whether Samyr® tablets can improve symptoms in patients with major depressive disorder who are not fully responding to their current treatment. The study compares Samyr® to a placebo to assess its effectiveness and safety.

Major Depression Disorder≤3 monthsConfirmation phase (III)6-10 visitsInvestigational MedicinesPartially RemotePsychiatry

Major Depression: Samyr Injection Study

We are testing whether Samyr, an injectable treatment, can improve symptoms in people with major depression who are not responding well to their current antidepressants. This study compares Samyr to a placebo to assess its effectiveness and safety.

Major Depression Disorder≤3 monthsConfirmation phase (III)11-15 visitsInvestigational MedicinesPsychiatry

Mucosal Melanoma: Anti-PD1 Immunotherapy Study

We are investigating whether a new treatment combining anti-PD1 therapy with surgery improves disease-free survival in patients with resectable mucosal melanoma. This study aims to evaluate the effectiveness and safety of this approach.

Melanoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteDermatologyOncology

Invasive Aspergillosis: Olorofim vs. AmBisome®

We are studying a new treatment called olorofim for patients with invasive aspergillosis to see if it works better and is safer than the standard treatment, AmBisome®. This trial will also look at how these treatments affect patients' quality of life.

Invasive Fungal Infection3-6 monthsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementInfectious DiseasesInternal Medicine

NY-ESO-1 T-Cells for Synovial Sarcoma and Liposarcoma

We are studying genetically engineered T cells in patients with synovial sarcoma and myxoid/round cell liposarcoma. The goal is to see if this treatment is effective and safe for those with specific tumor markers.

Myxoid and Round Cell LiposarcomaSynovial SarcomaEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

Long-Term Follow-Up of Adoptive Cell Therapies

We are monitoring individuals who received genetically modified cell treatments to check for any delayed side effects and how long these cells remain in the body. This study aims to ensure safety and understand the treatment's long-term effects.

Myxoid LiposarcomaMultiple MyelomaSynovial Sarcoma>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesPartially RemoteInternal MedicineOncology

Psychosis in Alzheimer's: ITI-1284 Study

We are evaluating a new medication, ITI-1284, for treating psychosis in patients with Alzheimer's disease. The study aims to see if it is more effective than a placebo in improving symptoms.

Psychosis associated with Alzheimer’s Disease3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementPsychiatry